Page last updated: 2024-11-04

norethynodrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6231
CHEMBL ID1387
CHEBI ID34895
SCHEMBL ID37838
MeSH IDM0014977

Synonyms (133)

Synonym
BIDD:ER0192
BRD-K80334323-001-03-5
19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-
MLS000069824 ,
smr000058915
PRESTWICK3_000024
(17beta)-17-ethynyl-17-hydroxyestr-5(10)-en-3-one
(17-alpha)-17-hydroxy-19-norpregn-5(10)-en-20-yn-3-one
brn 2389771
noretynodrel
19-nor-ethinyl-5,10-testosterone
ccris 486
17-beta-hydroxy-17-alpha-ethinyl-5(10)-estren-3-one
17-alpha-ethynyl-estr-5(10)-en-3-on-17-beta-ol
cb 8023
17-alpha-ethinyl-delta(super)-5,10-19-nortestosterone
13-methyl-17-ethynyl-17-hydroxy-1,2,3,4,6,7,8,9,11,12,13,14,16,17-tetradecahydro-15h-cyclopenta(a)-phenanthrene-3-one
noretynodrelum [inn-latin]
17alpha-ethynyl-19-nor-5(10)-androsten-17beta-ol-3-one
17-hydroxy(17alpha)-19-norpregn-5(10)-en-20-yn-3-one
17alpha-ethynyl-5(10)-estren-17-ol-3-one
17-alpha-ethynyl-19-nor-5(10)-androsten-17-beta-ol-3-one
17alpha-ethynyl-17beta-hydroxy-3-oxo-delta(sup 5(10))-estrene
19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-, (17alpha)-
hsdb 2951
17alpha-ethynyl-17beta-hydroxyestr-5(10)-en-3-one
17-ethinyl-5(10)-estraeneolone
19-nor-17-alpha-pregn-5(10)-en-20-yn-3-one, 17-hydroxy-
17-alpha-ethynyl-17-hydroxyestr-5(10)-en-3-one
17alpha-ethinyl-19-nor-delta-5(10)-androstene-17beta-ol-3one
noretinodrel [dcit]
17-alpha-ethynyl-5(10)-estren-17-ol-3-one
19-nor-17alpha-pregn-5(10)-en-20-yn-3-one, 17-hydroxy-
norethynodrel [progestins]
17alpha-ethinyl-5(10)estraen-17beta-ol-3-one
17-alpha-ethinyl-5,10-estrenolone
estr-5(10)-en-3-one, 17alpha-ethynyl-17-hydroxy-
lynestrol
17-alpha-ethinyl-17-beta-hydroxy-delta(sup 5(10))-estren-3-one
17alpha-ethynyl-17beta-hydroxy-delta(sup 5(10))-estren-3-one
17alpha-ethynyl-estr-5(10)-en-3-on-17beta-ol
17alpha-ethinyl-5,10-estrenolone
17alpha-ethinyl-17beta-hydroxy-delta(sup 5(10))-estren-3-one
17-alpha-ethynyl-17-beta-hydroxy-delta(sup. 5(10))-estren-3-one
17-hydroxy-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one
einecs 200-682-1
17alpha-ethinyl-delta(sup)-5,10-19-nortestosterone
17-alpha-ethynyl-17-beta-hydroxy-3-oxo-delta(sup 5(10))-estrene
nsc 15432
BPBIO1_000097
norethynodral
19-norethynodrel
infecundin
norethynodrel
norethinynodrel
nsc-15432
norethinodrel
17.alpha.-ethinyl-.delta.(sup)-5,10-19-nortestosterone
sc-4642
nsc15432
68-23-5
enidrel
PRESTWICK_883
cas-68-23-5
NCGC00016304-01
NCGC00179666-01
norethynodrel (usan)
noretynodrel (inn)
D05207
BSPBIO_000087
PRESTWICK2_000024
(8r,9s,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
wln: l e5 b666ov mutj e1 f1uu1 qq
estr-5(10)-en-3-one,17.alpha.-ethynyl-17-hydroxy-
SPBIO_002008
PRESTWICK0_000024
PRESTWICK1_000024
CHEMBL1387
chebi:34895 ,
HMS1568E09
HMS2095E09
tox21_110359
dtxsid3021069 ,
dtxcid60563
HMS2232J10
bdbm50410507
unii-88181aca0m
noretinodrel
noretynodrel [inn]
88181aca0m ,
noretynodrelum
norethynodrel [usan:usp]
19-norpregn-5(10)-en-20-yn-3-one,17-hydroxy-, (17a)-
norethynodrel component of enovid
13-methyl-17-ethynyl-17-hydroxy-1,2,3,4,6,7,8,9,11,12,13,14,16,17-tetradecahydro-15h-cyclopenta(a)phenanthren-3-one
noretynodrel [who-dd]
enovid component norethynodrel
norethisterone impurity d [ep impurity]
norethynodrel [orange book]
norethynodrel [vandf]
norethynodrel [mi]
noretynodrel [mart.]
norethynodrel [hsdb]
norethynodrel [usp impurity]
norethynodrel [usan]
CCG-220024
SCHEMBL37838
17-hydroxy-19-nor-17alpha-pregn-5(10)en-20-yn-3-one
17-.alpha.-ethynyl-17-.beta.-hydroxy-.delta.5(10)-estren-3-one
(17-.alpha.)-17-hydroxy-19-norpregn-5(10)-en-20-yn-3-one
5(10)-estren-3-one, 17alpha-ethynyl-17beta-hydroxy-
17.alpha.-ethynyl-17.beta.-hydroxy-3-oxo-.delta.5(10)-estrene
17.alpha.-ethinyl-17.beta.-hydroxy-.delta.5(10)-estren-3-one
17-.alpha.-ethynyl-17-.beta.-hydroxy-5(10)-estren-3-one
17.alpha.-ethinyl-.delta.5(10)-19-nortestosterone
17-.beta.-hydroxy-17-.alpha.-ethinyl-5(10)-estren-3-one
17-.alpha.-ethynyl-17-hydroxyestr-5(10)-en-3-one
17-.alpha.-ethinyl-.delta.5(10)-19-nortestosterone
17-ethynyl-17-hydroxyestr-.delta.5(10)-en-3-one, (17.alpha.,17.beta.)-
17.alpha.-hydroxy-19-norpregn-5(10)-en-20-yn-3-one
17.alpha.-ethynyl-17.beta.-hydroxy-.delta.5(10)-estren-3-one
(17beta-ethynyl-17-hydroxyestr-5(10)-en-3-one
OPERA_ID_1052
AKOS026749810
sr-01000721945
SR-01000721945-2
HMS3712E09
Q5659069
DB09371
EN300-7481217
CS-0013090
HY-B1341
(1r,3as,3br,9bs,11as)-1-ethynyl-1-hydroxy-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,6h,7h,8h,9h,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"A collaborative study of the analysis of mestranol in combination with norethindrone or norethynodrel by column chromatography and ultraviolet determination is presented."( Collaborative study of the analysis of mestranol in combination with norethindrone or norethynodrel.
Brunner, CA, 1971
)
0.25

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Research on combination norethynodrel-containing products revealed that the dosage was too high."( Oral contraception: a review.
Edgren, RA, 1991
)
0.28
" The dosage of Enovid was selected on the basis of preliminary experiments."( Reduction of carcinogen-induced breast cancer in rats by an anti-fertility drug.
Casey, AE; Griswold, DP; Weisburger, EK; Weisburger, JH, 1968
)
0.25
"19-nor steroids in high and medium dosage in continuous or cyclic combined regimens with oestrogen produce an endometrium characterized by hyperinvoluted glands, a prominent predecidual reaction, suppressed arterioles, and dilated venules."( Synthetic progestagen-oestrogen preparations and endometrial morphology.
Ober, WB, 1966
)
0.24
" In some, continuous therapy was given at the same dosage for 60-240 days."( Influence of norethynodrel and mestranol upon cervical dysplasia and carcinoma in situ.
Arsenault, J; Ayre, JE; Hillemanns, HG; Le GUERRIER, J; Leguerrier, J, 1966
)
0.24
" But again, both these extracts were capable of enhancing the mutation yield induced with an ineffective dosage of 2-acetylaminofluorene and N-nitrosopiperidine."( Enhancement of mutagenic activity in Salmonella by contraceptive steroids.
Allen, BE; Cox, JT; Epler, JL; Rao, TK, 1983
)
0.27
" During a four year period, 14 patients were treated with an oral contraceptive preparation which combined a reduced dosage of estrogen and progesterone."( [A new method for managing epistaxis in Osler's disease (author's transl)].
Budde, R, 1981
)
0.26
" An antithromboembolic effects was suggested with an increasing combined dosage of norethisterone acetate."( Thromboembolic disease and the steroidal content of oral contraceptives.
Swyer, GI, 1970
)
0.25
" Dosage is increased only when break through bleeding occurs."( Newer synthetic progestins for the treatment of endometriosis.
Kistner, RW, 1970
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxo steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency16.00100.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency0.03530.000221.22318,912.5098AID743035; AID743036; AID743040; AID743053; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.11690.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.03060.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency39.81073.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency11.35880.000323.4451159.6830AID743065; AID743067
survival motor neuron protein isoform dHomo sapiens (human)Potency1.77830.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)1.54880.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (920)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990868 (94.35)18.7374
1990's11 (1.20)18.2507
2000's26 (2.83)29.6817
2010's13 (1.41)24.3611
2020's2 (0.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (2.75%)5.53%
Reviews37 (3.63%)6.00%
Case Studies46 (4.51%)4.05%
Observational0 (0.00%)0.25%
Other909 (89.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]